trending Market Intelligence /marketintelligence/en/news-insights/trending/EG6oOLZlb_6EXg__1xeYug2 content esgSubNav
In This List

HVIVO director resigns

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


HVIVO director resigns

HVIVO PLC said Graham Yeatman stopped being a director of the company, effective Dec. 31, 2018.

As previously announced in September 2018, Yeatman also stepped down as hVIVO's chief financial and business officer.

He joined the company's board as finance director in 2011 and was promoted to the chief financial and business officer post in 2015.

The company has named Shelley Fraser to replace Yeatman as finance director.

London-based hVIVO is developing a human-based clinical trial platform for drug and vaccine development in respiratory and infectious diseases.